Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Does The Market Size Of The Calcitonin Gene-Related Peptide Receptor Antagonist Industry Compare Between 2025 And 2029?
The calcitonin gene-related peptide receptor antagonist market has seen substantial growth recently. It is projected to expand from $2.06 billion in 2024 to $2.30 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 11.2%. This historical growth can be linked to the increase in clinical trials demonstrating efficacy, escalating healthcare spending globally, a rise in migraine disorder diagnosis rates, the increasing uptake of preventive migraine therapies, and a robust pipeline of CGRP antagonist molecules.
The calcitonin gene-related peptide receptor antagonist market size is anticipated to undergo swift expansion in the coming years. This market is predicted to reach $3.48 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.0%. This expansion during the forecast period is fueled by factors such as favorable regulatory approvals, increased research funding, the rising adoption of novel migraine prevention therapies, and an expanding geriatric population. Significant trends anticipated in this period include the development of oral small molecules, wearable devices for triggered dosing, long-acting injectable formulations, nanoparticle drug carriers, and ongoing gene therapy investigations.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25715&type=smp
Which Industry Drivers Are Expected To Accelerate The Calcitonin Gene-Related Peptide Receptor Antagonist Market From 2025 To 2029?
The rising incidence of migraine is projected to propel the expansion of the calcitonin gene-related peptide receptor antagonist market in the future. Migraine is described as a severe headache often causing throbbing discomfort, typically affecting one side of the head. This increasing prevalence of migraine stems from heightened stress due to busy urban lifestyles, irregular sleep patterns, and greater exposure to noise, pollution, and bright lights as more people relocate to cities. Calcitonin gene-related peptide receptor antagonists aid in treating migraine by blocking CGRP, a protein that dilates blood vessels and conveys pain signals during a migraine attack, thereby reducing headache pain and other associated symptoms. For instance, in April 2024, a report from the National Library of Medicine, a US-based national library, revealed that roughly 61,204 individuals in the US were diagnosed with migraines by a physician in 2022, representing an increase of 5.5% from 2021. Therefore, the growing occurrence of migraine is a key factor driving the calcitonin gene-related peptide receptor antagonist market’s growth.
What Are The Major Segment Types Covered In The Calcitonin Gene-Related Peptide Receptor Antagonist Market?
The calcitonin gene-related peptide receptor antagonist market covered in this report is segmented –
1) By Type: Small Molecule Antagonists, Monoclonal Antibodies, Peptide-Based Antagonists
2) By Drug Type: Zavegepant, Ubrogepant, Olcegepant, Telcegepant, Rimegepant, Other Drug Types
3) By Application: Migraine Treatment, Pain Management, Cardiovascular Conditions, Bone Disorders
4) By End-Users: Hospitals, Clinics, Homecare Settings, Pharmaceutical Companies
Subsegments:
1) By Small Molecule Antagonists: Oral Small Molecule Antagonists, Intranasal Small Molecule Antagonists, Injectable Small Molecule Antagonists
2) By Monoclonal Antibodies: Erenumab, Fremanezumab, Galcanezumab, Eptinezumab
3) By Peptide-Based Antagonists: CGRP Fragment-Based Antagonists, Peptidomimetic CGRP Antagonists
Which Key Trends Are Expected To Influence The Calcitonin Gene-Related Peptide Receptor Antagonist Market In The Coming Years?
Major companies within the calcitonin gene-related peptide receptor antagonist market are prioritizing approvals for innovative products, such as oral CGRP receptor antagonists, to bolster migraine treatment effectiveness, broaden therapeutic applications, and introduce more convenient administration methods. Oral CGRP receptor antagonists are small-molecule medications designed to inhibit CGRP, a protein associated with migraine attacks, thereby assisting in migraine prevention. As an illustration, in April 2023, AbbVie Inc., a US-based biotech organization, secured approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) for the management of chronic migraine in adults. QULIPTA (atogepant) represents an oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist developed for the prophylactic treatment of migraine in adults, now authorized for both episodic and chronic migraine within the United States. It functions by impeding the activity of CGRP, a protein that becomes elevated during migraine episodes and contributes to pain signaling and inflammation in the brain. QULIPTA is provided in tablet strengths of 10 mg, 30 mg, and 60 mg, with the 60 mg dose specifically investigated for chronic migraine prevention.
Which Global Market Leaders Are Shaping The Future Of The Calcitonin Gene-Related Peptide Receptor Antagonist Sector?
Major companies operating in the calcitonin gene-related peptide receptor antagonist market are Pfizer Inc., Merck & Co. Inc. , AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Sosei Group Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A., Alder BioPharmaceuticals, Inc. , H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd., Biosynth Carbosynth , Seurat Therapeutics Inc., Satsuma Pharmaceuticals Inc., Allergan plc , Brise Pharmaceutical (Shanghai) Co Ltd., Nuvie Biopharma Inc.
Download The Full Report For Exclusive Market Findings:
How Does The Calcitonin Gene-Related Peptide Receptor Antagonist Market Perform Across Key Geographic Regions?
North America was the largest region in the calcitonin gene-related peptide receptor antagonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide receptor antagonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Calcitonin Gene-Related Peptide Receptor Antagonist Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25715&type=smp
Browse Through More Reports Similar to the Global Calcitonin Gene-Related Peptide Receptor Antagonist Market 2025, By The Business Research Company
Peptide Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Cc Chemokine Receptor Type 5 Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report
Muscarinic Acetylcholine Receptor Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model